Patents by Inventor Kazuma Suda

Kazuma Suda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ROR1-positive mesenchymal stem cells and method for preparing same, pharmaceutical composition containing ROR1-positive mesenchymal stem cells and method for preparing same, and method for preventing or treating disease using ROR1-positive mesenchymal stem cells
    Patent number: 11707488
    Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.
    Type: Grant
    Filed: August 29, 2016
    Date of Patent: July 25, 2023
    Assignee: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Yoshifumi Ikeyama, Hiroyuki Nishida, Tomohiro Tsuda, Eiko Uno, Masayo Yumoto, Kazuma Suda, Mihoko Yoshino, Xuan Trung Ngo
  • ROR1-POSITIVE MESENCHYMAL STEM CELL-CONTAINING PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASE ASSOCIATED WITH FIBROSIS, METHOD FOR PREPARING SAME, AND METHOD FOR PREVENTING OR TREATING DISEASE ASSOCIATED WITH FIBROSIS USING ROR1-POSITIVE MESENCHYMAL STEM CELLS
    Publication number: 20200069740
    Abstract: The purpose of the present invention is to provide the following: novel mesenchymal stem cells having an excellent therapeutic effect on various diseases, particularly diseases associated with fibrosis; and a pharmaceutical composition containing such mesenchymal stem cells. The present invention is a therapeutic agent for fibrosis that contains ROR1-positive mesenchymal stem cells and/or a culture supernatant thereof and that is for preventing or treating a disease associated with fibrosis. The mesenchymal stem cells are CD29-, CD73-, CD90-, CD105-, and CD166-positive and are preferably derived from the umbilical cord or fat. In addition, the abovementioned disease associated with fibrosis is preferably a liver disease, a lung disease, a kidney disease, or a heart disease.
    Type: Application
    Filed: March 8, 2018
    Publication date: March 5, 2020
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Hikari Hasegawa, Masayo Yumoto, Yoshifumi Ikeyama, Hiroyuki Nishida, Tomohiro Tsuda, Eiko Uno, Kazuma Suda, Mihoko Yoshino, Xuan Trung Ngo
  • ROR1-POSITIVE MESENCHYMAL STEM CELLS AND METHOD FOR PREPARING SAME, PHARMACEUTICAL COMPOSITION CONTAINING ROR1-POSITIVE MESENCHYMAL STEM CELLS AND METHOD FOR PREPARING SAME, AND METHOD FOR PREVENTING OR TREATING DISEASE USING ROR1-POSITIVE MESENCHYMAL STEM CELLS
    Publication number: 20180333436
    Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.
    Type: Application
    Filed: August 29, 2016
    Publication date: November 22, 2018
    Applicant: ROHTO PHARMACEUTICAL CO., LTD.
    Inventors: Yoshifumi Ikeyama, Hiroyuki Nishida, Tomohiro Tsuda, Eiko Uno, Masayo Yumoto, Kazuma Suda, Mihoko Yoshino, Xuan Trung Ngo
  • Ameliorating Agent for Metabolic Syndrome
    Publication number: 20090123582
    Abstract: The object is to provide a food-derived effective ingredient which can promote the reduction in accumulated fats or the like. Disclosed is a body fat reduction-promoting agent, a leptin production-promoting agent, an anorexigenic agent, a PAI-1 production-suppressing agent or an anti-thrombotic agent, each comprising an extract from a chestnut astringent skin as an active ingredient. The extract from a chestnut astringent skin, which is a natural component, can be used as an extremely safe body fat reduction-promoting agent, leptin production-promoting agent, anorexigenic agent, PAI-1 production-suppressing agent or anti-thrombotic agent. Particularly, the body fat reduction-promoting agent can reduce an accumulated visceral fat and therefore can directly prevent obesity.
    Type: Application
    Filed: March 23, 2007
    Publication date: May 14, 2009
    Inventors: Akiko Kuwahara, Ayako Nakanishi, Kazuma Suda